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ttp://dx.doi.org/10.1016/j.ajpath.2015.01.020Neutrophil migration to sites of inﬂammation and the subsequent execution of multiple functions are
designed to contain and kill invading pathogens. These highly regulated and orchestrated processes are
controlled by interactions between numerous receptors and their cognate ligands. Unraveling and
identifying those that are central to inﬂammatory processes may represent novel therapeutic targets for
the treatment of neutrophil-dominant inﬂammatory disorders in which dysregulated neutrophil recruit-
ment, function, and elimination serve to potentiate rather than resolve an initial inﬂammatory insult. The
ﬁrst G proteinecoupled receptor to be described on human neutrophils, formyl peptide receptor 1 (FPR1),
is one such receptor that plays a signiﬁcant role in the execution of these functions through multiple
intracellular signaling pathways. Recent work has highlighted important observations with regard to both
receptor function and the importance and functional relevance of FPR1 in the pathogenesis of a range of
both sterile and infective inﬂammatory conditions. In this review, we explore the multiple components of
neutrophil migration and function in both health and disease, with a focus on the role of FPR1 in these
processes. The current understanding of FPR1 structure, function, and signaling is examined, alongside
discussion of the potential importance of FPR1 in inﬂammatory diseases suggesting that FPR1 is a key
regulator of the inﬂammatory environment. (Am J Pathol 2015, 185: 1172e1184; http://dx.doi.org/
10.1016/j.ajpath.2015.01.020)Supported by Wellcome Trust grants WT096497 and WT094415
(D.A.D. and C.D.L.) and by Medical Research Council grant MR/
K013386/1 (C.H. and A.G.R.).
Disclosures: None declared.More than 100 years ago, Metchnikoff described micro-
phagocytes as important responders to sterile injury in
starﬁsh larvae.1 Now known to be neutrophils, they are key
effector cells of the innate immune system and are pivotal
in the containment and clearance of initial noxious stimuli
of either infective or sterile origin.2 Accounting for 50%
to 70% of circulating human leukocytes, these poly-
morphonuclear granulocytes patrol the vasculature and
rapidly migrate into tissues in response to chemotactic sig-
nals.3 On arrival, neutrophils execute a variety of antimi-
crobial functions, including the generation of reactive
oxygen species (ROS), phagocytosis of pathogens and dead
and dying tissue, degranulation with the release of a variety
of toxic products, expulsion of neutrophil extracellular
traps, and paracrine signaling to recruit other cell types.4
Disruption of these processes or overwhelming neutrophil
recruitment can cause signiﬁcant dysregulation of thestigative Pathology.
.inﬂammatory cascade, resulting in failed resolution of
inﬂammation, tissue injury, and acute or chronic disease.
The predominant mechanisms through which neutrophils
sense inﬂammatory stimuli and surrounding environments are
a plethora of cell surface receptors principally within the G
proteinecoupled receptor (GPCR) family. The ﬁrst GPCR to
be described on the human neutrophil was formyl peptide
receptor 1 (FPR1) which, when activated, triggers a wide
variety of functions, including chemotaxis, degranulation,
ROS production, and phagocytosis.5,6 Although descriptions
of FPR1 functions in vitro are well documented, increasing
attention is being paid to its in vivo role, inﬂuence, and
FPR1 in Acute Neutrophilic Inﬂammationimportance in the pathogenesis of both infective and sterile
acute inﬂammatory disease.
The principal ligands for FPR1 are bacterial and mito-
chondrial formylated peptides, actively secreted by invading
pathogens or passively released from dead and dying host
cells after tissue injury. During infection, pathogens target
and destroy host tissue with the simultaneous release of both
bacteria-derived (when the pathogen is of bacterial origin)
and host-derived formylated peptides (from host mito-
chondria), thereby linking FPR1 in both infective and sterile
inﬂammatory processes. This review therefore provides an
overview of the structure, signaling, and pathological
functions of FPR1 as well as a focus on the recent de-
velopments in the understanding of formylated peptides and
neutrophil FPR1 in the context of infective and sterile
inﬂammation.Figure 1 Structure of the FPR1 receptor and key polymorphisms within
the protein. Formyl peptide receptor 1 (FPR1) as a classic G-proteinecoupled
receptor has seven transmembrane-spanning regions with an extracellular
N-terminus, whereas the C-terminus is found within the cytoplasm. Multiple
amino acid substitutions have been found within the protein: recognized
constitutive isoforms (green; FPR-26, FPR-98, and FPR-G6), polymorphisms
associated with disease states including juvenile and aggressive periodon-
titis (red), hypertension in young adults (orange), gastric cancer (pink;
denotes D192K), and those that have been observed but whose functional
signiﬁcance remains uncertain (blue).Formyl Peptide Receptors
The binding of the N-formyl methionine motifs of bacterial-
and mitochondrial-derived peptides to FPR1 was initially
described over 3 decades ago and was the starting point for
the subsequent dissection of the many G-protein signaling
cascades within neutrophils.7,8 The human FPR family
constitutes FPR1, FPR2/ALX (lipoxin receptor), and FPR3,
which are well-conserved GPCRs that have pluripotent and
diverse roles in the initiation, propagation, and resolution of
inﬂammation.9
FPR1 was the ﬁrst neutrophil GPCR to be cloned and
sequenced, identifying it as a 350-residue protein with seven
hydrophobic segments (Figure 1).5 A subsequent study
characterized FPR1 as a seven-transmembrane receptor with
the N-terminus and three loops exposed on the cell surface
for ligand interactions and the C-terminus and the remaining
loops found within the cytoplasm necessary for intracellular
signaling.10 Using low-stringency hybridization with FPR
cDNA as the probe, two separate but relatively conserved
low-afﬁnity receptors, initially termed FPR-like 1 (FPRL1)
and FPR-like 2 (FPR2L), were cloned from an mRNA
library of neutrophil-like promyelocytic HL-60 cells. These
receptors have since been renamed FPR2/ALX and FPR3,
respectively, as more has become known about their distinct
biochemical and physiological roles.6 All three receptors are
clustered together on chromosome 19q13.3 and share sig-
niﬁcant sequence homology. FPR1 has 69% amino acid
identity with FPR2 and 56% with FPR3, whereas FPR2 and
FPR3 share 83% identity.11Formyl Peptide Receptor 1
Regulation of FPR1 Expression
Constitutively expressedon the surface of quiescent neutrophils,
FPR1 receptor expression is rapidly up-regulated in response to
a wide number of inﬂammatory stimuli. In vitro, these stimuli
include lipopolysaccharide (LPS), platelet-activating factor,The American Journal of Pathology - ajp.amjpathol.orgunmethylated CpG oligodinucleotides, and tumor necrosis
factor a12e15; FPR1 receptor up-regulation has also been
described in the circulating neutrophils of patients with
emphysema, Crohn disease, and sepsis.16e18 Such a rapid
increase in FPR1 expression indicates its preformed pres-
ence within the cell. Subcellular fractionation and the study
of neutrophil transcription within the bone marrow have
determined that FPR1 synthesis occurs late in neutrophil
maturation, with the receptor subsequently stored in azur-
ophilic granules (also known as primary granules) and
secretory vesicles.14,19 In response to agonists such as
platelet-activating factor, secretory-vesicle FPR1 alone is
mobilized; however, in response to powerful stimuli such
as phorbol myristate acetate, azurophilic-granule FPR1
also localizes to the cell surface.14
Alongside FPR1 transport from intracellular compart-
ments, neutrophil activation increases FPR1 protein synthe-
sis. In nonstimulated cells, FPR1 mRNA is unstable, with a
t1/2 of approximately 90 minutes.
20 After incubation with
LPS, increased FPR1 gene transcription occurs along with
stabilization of the mRNA transcript (t1/2, approximately 20
hours), allowing for increased synthesis of the receptor. LPS,
through myeloid differentiation marker MyD88edependent
signaling pathways, is a powerful inducer of FPR1 synthesis
in mature neutrophils, whereas tumor necrosis factor a and
other proinﬂammatory mediators also induce a similar
response.21,22 The increases in receptor cycling and protein
synthesis therefore increase FPR1 at the cell surface, facili-
tating the perpetuation of the inﬂammatory response as1173
Table 1 The Principal Cell Types that Express Human Formyl
Peptide Receptors and the Predominant Agonists and Antagonists
of the Receptors
Receptor/cell type Agonists Antagonists
FPR1
Neutrophils8 N-formylated peptides7 Cyclosporin H30
Macrophages20 Synthetic fMLF5 Cyclosporin A29
Monocytes31 Cathepsin G32 Boc-MLF (Boc-1)10
Dendritic cells33 FAM19A434 Boc-FLFLFL (Boc 2)10






Neutrophils37 N-formylated peptides38 Boc-MLF (Boc-1)10
Macrophages39 fMLF40 Boc-FLFLFL (Boc 2)10
Monocytes41 LL-3741 WRW4 peptide10
Dendritic cells9 Serum amyloid A9
Microglia9 b-Amyloid9
T lymphocytes9 HIV gp41-derived
peptide9










*Anti-inﬂammatory agonist; the ligands described elicit functional
responses in a number of cell types.
Ac2-26, N-terminal peptide of annexin 1; Boc-FLFLFL, Boc-Phe-Leu-Phe-Leu-
Phe-OH; Boc-MLF, Boc-Met-Leu-Phe-OH; CHIPS, chemotaxis inhibitory protein
of Staphylococcus aureus; FAM19A4, family with sequence similarity 19, member
A4; fMLF, formyl-methyl-leucine-phenylalanine; FPR, formyl peptide receptor;
gp, glycoprotein; LL-37, leucine, leucine 37; WRW4, Trp-Arg-Trp-Trp-Trp-Trp-
CONH2 (WRWWWW).
Dorward et algreater numbers of receptor are available on each cell to bind
free ligand.
Polymorphisms within FPR1
With increasing attention being paid to the role of interindi-
vidual differences in response to infection and inﬂammation,
variation in receptor number and function through poly-
morphisms within the FPR1 gene have been studied. Three
isoforms of human FPR1 exist: FPR-26 (V101, N192, E346),
FPR-98 (L101, N192, A346), and FPR-G6 (V101, K192,
A346). These differ in amino acids 101 (the top of the third
transmembrane loop), 192 (center of the second intracellular
loop), and 346 (end of the C-terminus) (Figure 1).22,23
Functionally, FPR-98 and FPR-G6 have a partial defect
in Gi-protein coupling relative to the more constitutively
active FPR-26, with the amino acid glutamic acid at po-
sition 346 essential for the G-protein signaling of the latter
isoform.24 Alongside these naturally occurring variants of
FPR1, at least 30 other single-nucleotide polymorphisms
(SNPs) have been described within the FPR1 gene.6
Neutrophils isolated from individuals with localized ju-
venile periodontitis demonstrate impaired responsiveness to
formyl-methyl-leucine-phenylalanine (fMLF; alias fMLP),
perhaps explaining increased rates of periodontal infection
through reduced migration or impaired bacterial killing
capacity.25 SNPs F110S and C126W in the second intra-
cellular loop of the receptor may well account for this
phenotype. Furthermore, a T348T/T mutation, although not
altering FPR1 receptor number, was associated with
impaired fMLF-induced neutrophil chemotaxis and aggres-
sive periodontitis in an African-American population.26
Meanwhile, the association of the C32T SNP with the
development of hypertension in younger adults, as well as
the D192K polymorphism with the onset of gastric carci-
noma in an elderly Japanese population, have also been
described, although their mechanistic and functional rele-
vance is yet to be determined.27,28 In contrast, the V101L
SNP is associated with increased binding afﬁnity for the
FPR1 antagonist cyclosporin H.29 With increasing applica-
tion of genome-wide association studies, it remains to be
seen whether other SNPs are associated with altered sus-
ceptibility to inﬂammatory diseases or infection.
FPR1 Ligands
Although it was initially thought that FPR1 only bound
N-formylated peptides,7 it is now widely recognized that the
formyl group is not a prerequisite for receptor binding. The
N-formylated version of any peptide containing a methio-
nine residue at the 50 terminus is at least 100-fold more
potent than the identical nonformylated peptide. However, if
the peptide contains ﬁve or more amino acids, the non-
formylated moieties can also bind and activate FPR1.23 This
ﬁnding has been further substantiated by the description
of endogenous nonformylated ligands that bind FPR1,
including cathepsin G, annexin A1 (AnnA1), and the
recently described cytokine family with sequence similarity117419, member A4, although their functional effects differ from
those of fMLF/FPR1-described functions (Table 1).34,42 For
example, the neutrophil granule protein cathepsin G binding
to FPR1 is unable to induce intracellular calcium ﬂux but
does, however, result in mitogen-activated protein kinase
(MAPK) phosphorylation and neutrophil chemotaxis and
dendritic cell recruitment.32 It is postulated that this
discrepancy in receptor function is likely attributable to low-
afﬁnity binding, thereby inducing isolated components of
the inﬂammatory cascade.10 Similarly, AnnA1 and its
N-terminal peptide derivative Ac2-26 bind to FPR1 and
induce anti-inﬂammatory and proresolution effects rather
than a proinﬂammatory response through a variety of ef-
fects, including receptor heterodimerization with FPR2.35,42
FPR1 Binding Properties
Much is known about the structure and function of FPR1 at a
molecular level and its interaction with the Escherichiaajp.amjpathol.org - The American Journal of Pathology
Figure 2 Intracellular signaling events after
FPR1 receptor activation. After binding of ligand
to formyl peptide receptor 1 (FPR1), conversion of
guanosine diphosphate to guanosine triphosphate
induces dissociation of the a from the bg sub-
units. These trigger a range of intracellular kinase
pathways, resulting in the induction of a variety of
cell functions, including neutrophil chemotaxis,
degranulation, superoxide anion production, and
transcriptional activity. The predominant signaling
pathways are those of phosphoinositide-3 kinase
(PI3K), mitogen-activated protein kinase (MAPK),
and phospholipase C. The latter triggers release of
intracellular calcium from the endoplasmic reticu-
lum to activate protein kinase C (PKC) and subse-
quent reactive oxygen species production, whereas
PI3K triggers protein kinase B (alias Akt)-mediated
and phosphoinositol-3,4,5-trisphosphate (PIP3)-
mediated signaling, with a variety of cellular
effects. With PI3K pulled toward the plasma
membrane by the b and g G-protein subunits (Gb
and Gg), activation of Ras family proteins and
MAPK further contributes to oxidative burst and
chemotaxis. CDC, cell division control protein;
DAG, diacyl glycerol; Ga, G-protein a; GEF, guanine
nucleotide exchange factor; Grb, growth factor
receptorebound protein; IP3, inositol tri-
sphosphate; MEKK, mitogen-activated protein ki-
nase kinase; PA, phosphatidic acid; PLCb,
phospholipase Cb; PLD, phospholipase D; RAF,
rapidly accelerated ﬁbrosarcoma; Sos, son of sev-
enless; WASP, Wiskott-Aldrich syndrome protein.
FPR1 in Acute Neutrophilic Inﬂammationcoliederived prototypic synthetic ligand fMLF. Firstly, the
formyl groupat theN-terminus allowshydrogenbond formation
to a hydrogen acceptor within the binding pocket. Sec-
ondly, the methionine side chain may occupy a hydropho-
bic pocket within the receptor, with the sulfur atom in the
ligand interacting with a positively charged portion of the
receptor. Finally, further hydrophobic interactions may
occur between the leucine and phenylalanine residues and
FPR1.10 After binding to FPR1, fMLF is internalized
within approximately 30 seconds and stimulates a variety of
intracellular signaling cascades, resulting in a number of
cellular responses. Within neutrophils, these include
chemotaxis, ROS production, degranulation, cytokine
expression, phagocytosis, and changes in cell surface
marker expression.23,45,46
FPR1 Desensitization
As discussed, regulation of GPCR function is essential in vivo
for controlling neutrophil functions, including chemotaxis and
the exact localization of cells to the inﬂammatory site.9,23,47
After FPR1-ligand binding, the cell rapidly becomes unre-
sponsive to subsequent stimulation by the same ligand
(homologous desensitization). Multiple distinct processes
account for this change in cell function, including receptor
internalization and desensitization.10 The latter is mediated
by phosphorylation of multiple serine and threonineThe American Journal of Pathology - ajp.amjpathol.orgresidues within the carboxy-terminal, leading to G-protein
dissociation and disruption of intracellular signaling path-
ways, a process that is governed in part by ERK1/2eGPCR
kinase 2 (GPK2) and arrestin binding.48,49 Meanwhile, re-
ceptor internalization predominantly occurs after C-termi-
nal phosphorylation through b-arrestineindependent and
noneclathrin-mediated endocytosis.6,50
Heterologous desensitization of FPR1 can also occur
after activation of CD88 [a complement component 5a
(C5a) receptor] or chemokine (C-X-C motif) receptor 2
CXCR2; (an IL-8 receptor) due to shared components of
intracellular signaling molecules and occurs principally
through protein kinase Cemediated pathways.51 Due to the
intracellular signaling hierarchy that exists, however, the
capacity for FPR1’s heterologous desensitization of other
receptors far outstrips their reciprocal ability to inhibit
FPR1 function,52 which was recently highlighted by the
observation that the activation of FPR1 in monocytes in-
duces cross-desensitization of CCR1 but not CCR2.52 This
observation suggests the ability of FPR1 to act as a regulator
of chemoreceptor hierarchy with regard to prioritizing not
only its own signaling but also that of other potent and
important agonists, such as those that bind CCR2.53
Importantly, these reductions in cell surface receptor num-
ber and function can be relatively short-lived, as receptor
and ligand dissociate from each other after internalization1175
Dorward et aland the receptor returns to the cell surface available for
further ligand binding.
Intracellular Signaling
Characterization of the FPR1 signaling cascades has been
conducted with fMLF as the stereotypical ligand and has
revealed a highly complex and integrated chain of intra-
cellular signaling events.10,23 Binding to FPR1 results in
Gi-type G-protein activation, with the conversion of GDP
to GTP inducing the dissociation of a from the bg subunits
(Figure 2). The latter liberated subunits activate both
the phospholipase Cb and phosphoinositide 3-kinase g
(PI3Kg) signaling cascades. Phospholipase Cb hydrolyses
membrane-bound phosphoinositol-4,5-bisphosphate into
diacylglycerol and inositol trisphosphate to mediate the
release of intracellular calcium stores, principally from the
endoplasmic reticulum. These events subsequently acti-
vate protein kinase C and are central to NADPH oxidase
ROS production.54 Meanwhile, PI3Kg-mediated conver-
sion of phosphoinositol-4,5-bisphosphate to phosphoino-
sitol-3,4,5-trisphosphate acts as the principal regulator of
neutrophil cytoskeletal reorganization and respiratory
burst after FPR1 activation as well as inﬂuences the
chemotactic response.10,47
As the bg subunits activate PI3Kg and pull it toward the
plasma membrane, the activity of Src-like tyrosine kinases
increases with the phosphorylation of the Src homology
2 domainecontaining (Shc) adaptor protein, which, in turn,
increases the association with growth factor receptore
bound protein 2 and son of sevenless and subsequently
activates MAPK signaling pathways. ERK and p38 MAPK
predominantly inﬂuence chemotaxis and FPR1-mediated
transcriptional activity.10 Meanwhile, the activation of
guanineenucleotide exchange factors induces the activa-
tion of the Rho GTPases [Rho, Rac, and cell division control
protein 42 (CDC42)]. These, in turn, regulate ROS pro-
duction through control of the formation of NADPH oxi-
dase complex6 as well as inﬂuence leukocyte adhesion,
transmigration, actin polymerization, and phagocytosis.55
Although much of this work is well recognized, recent
work using antibodies speciﬁc to C-terminal phosphoryla-
tion sites within the FPR1 protein has demonstrated that in
some cases, in particular in the context of inﬂammatory
bowel disease, G-proteineinsensitive, formylated peptidee
dependent FPR1 phosphorylation may also occur. This
observation was noted to be predominantly at the surface of
colonic crypt abscesses, leading Leoni et al56 to postulate
that this possible reactivation of FPR1 at distinct sites of
inﬂammation may contribute to perpetuation of the acute
and often deleterious inﬂammatory response.
New facets of the conventional understanding of FPR1
signaling within neutrophils have begun to emerge in recent
years, for example, the appreciation of its interconnection
with autocrine release of ATP and subsequent purinergic
signaling. Recent work by Bao et al57 demonstrated that
FPR1 signaling induces a rapid, but reversible, increase in1176the mitochondrial membrane potential within neutrophils,
with an associated oxidative burst and extracellular release
of ATP through pannexin 1 channels. Despite the conven-
tional understanding that neutrophil-mediated ATP pro-
duction occurs through glycolysis, researchers demonstrate
that the initial burst of ATP is mitochondria derived and
important in initiating the FPR/purinergic response. The
autocrine ATP appears to then bind purinergic P2Y2 and
P2X receptors to augment neutrophil chemotaxis, intracel-
lular calcium ﬂux, and p38 and ERK p42/44 MAPK
signaling but appears to have little effect on fMLF-mediated
degranulation and phagocytosis. Interestingly, pannexin 1
channels and the purinergic receptors accumulate at the
leading edge of the polarized neutrophil, providing oppor-
tunity for coordinated migratory activity.57e59
Also, localizing to the leading edge of the migrating
neutrophil is the receptor of urokinase-type plasminogen
activator serine protease to facilitate urokinase-type plas-
minogen activatoremediated degradation of the extracellular
matrix, thus allowing for extravascular neutrophil transit. It
is understood that urokinase-type plasminogen activator re-
ceptor expression is necessary for fMLF-induced chemotaxis
through a variety of means, including the colocalization of
FPR1 and b1-integrins at the cell surface, with urokinase-type
plasminogen activator receptor acting as a bridging molecule
to facilitate their respective functions.60 These novel obser-
vations, therefore, provide further insight into the highly
regulated and integrated crosstalk between different ligands
and their receptors in ﬁne-tuning the functional response to
inﬂammatory agents.
Formyl Peptide Receptor 2
In contrast to the speciﬁcity of FPR1, its relative FPR2/
ALX is a highly promiscuous receptor that binds fMLF with
low afﬁnity.40 It was one of the ﬁrst descriptions of a re-
ceptor capable of binding lipids, peptides, and proteins with
ligands including serum amyloid A, lipoxin A4, and AnnA1
and has been reviewed in detail elsewhere.9,37,61 Impor-
tantly, these ligand-speciﬁc interactions are able to induce
either proinﬂammatory or proresolution/anti-inﬂammatory
effects. With regard to binding to formylated peptides, the
binding afﬁnity of FPR2 is determined principally by the
charge of the C-terminus of peptide, contrary to FPR1
which, as discussed in FPR1 Ligands, is N-terminal
dependent.
Binding of serum amyloid A or the cathelicidin-
associated antimicrobial peptide leucine, leucine-37
(LL37) to FPR2/ALX results in proinﬂammatory responses
with neutrophil NF-kB activation and cytokine release,
increased neutrophil recruitment to sites of inﬂammation,
and increased neutrophil lifespan.41,62 In contrast, binding
of AnnA1 inhibits neutrophil migration, promotes neutro-
phil apoptosis, increases the rate of macrophage phagocy-
tosis of apoptotic cells, and skews the macrophages toward
a less proinﬂammatory phenotype.39 Lipoxin A4, againajp.amjpathol.org - The American Journal of Pathology
FPR1 in Acute Neutrophilic Inﬂammationthrough FPR2/ALX, inhibits neutrophil migration while
concomitantly augmenting monocyte recruitment. These
distinct effects elicited from ligand binding to the same
receptor have recently been attributed to different dimer-
ization states after agonist binding that alter receptor
conformation and subsequent intracellular signaling.42
Formyl Peptide Receptor 3
Distinct from the other members of the FPR family, the
function of FPR3 remains relatively poorly understood.
While not expressed on human neutrophils, it is found in
eosinophils, monocytes, macrophages, and dendritic cells,
leading to speculation that it may play a role in the path-
ogenesis of allergic disease.63 FPR3 is relatively insensi-
tive to formylated peptides, and few speciﬁc endogenous
ligands have been identiﬁed. F2L, an endogenous
21eamino acid acetylated amino-terminal peptide, is the
most speciﬁc ligand described to date.64 Derived from
cleavage of heme-binding protein 1 by cathepsin D, F2L
activates FPR3 in low nanomolar concentrations.44 In
doing so, it induces monocyte intracellular calcium ﬂux,
ERK1/2 phosphorylation, and chemotaxis while also aug-
menting LPS-mediated IL-12 production in dendritic cells,
thereby inhibiting their maturation.33,64 Humanin, a neu-
roprotective peptide, also binds with high afﬁnity to both
FPR2 and FPR3.43 Despite the high sequence homology
with FPR2/ALX, the behavior of FPR3 is surprising, with
signiﬁcantly higher basal levels of receptor phosphory-
lation and internalization and relative insensitivity to
common FPR2/ALX ligands.65 This observation has led
to the hypothesis that it may also act as a decoy receptor
to bind extracellular ligands, thereby regulating the
function of other formylated peptide receptors.65
Although there is likely to be some functional overlap
with FPR2/ALX, the true functional role of FPR3 and its
relevance in vivo remain to be determined.
Mouse FPR Receptors
FPR1 has been described across several species, including
horse, rabbits, and rodents, with marked differences in
functional responses to formylated peptides observed.6 In
comparison to the three FPR receptors described in humans,
the mouse genome encodes multiple FPR-related receptors
from chromosome 17A3.2.66 Fpr1 is the murine orthologue
of human FPR1, sharing 77% homology, expression on
similar cell types, and induction of the same effects of
neutrophil chemotaxis, degranulation, cytokine production,
and phagocytosis.67 Genes Fpr2 and Fpr3 together encode
receptors that mimic human FPR2/ALX. Fpr2 encodes the
ALX receptor speciﬁc for lipoxin A4, whereas Fpr3 encodes
Fpr2, which binds formylated peptides, serum amyloid A,
and other similar ligands.6 Similarities between murine Fpr2
and human FPR3 with regard to responsiveness to F2L have
also been observed.68 At present, the function and cognateThe American Journal of Pathology - ajp.amjpathol.orgligands of the remaining murine Fpr receptors are poorly
characterized and understood. Fpr-related sequences 3, 4, 6,
and 7 may function as chemoreceptors in vomeronasal
olfactory sensory neurons,69 whereas Fpr-related sequence 8
appears to affect the lifespan of mice, although the reason
for this remains unknown at present.66
Although there is relatively high sequence homology of
FPR1 between humans and mice, and the intracellular
domain structure is highly conserved, there are distinct
differences in the afﬁnity of murine Fpr1 for fMLF, which
is approximately 100-fold less than that of its human
counterpart.68 This difference in afﬁnity is attributed to
alterations in the folding of the transmembrane and extra-
cellular domains, as determined by the apposition of
multiple noncontiguous residues.70 Although differences
in the afﬁnity of a receptor to prototypic E. coliederived
fMLF are described, it should be noted that, with regard
to other bacterial formylated peptides, murine Fpr1 remains
a high-afﬁnity receptor, in particular to Staphylococcus
aureus, Listeria monocytogenes, and mitochondria-derived
formylated peptides.68 Although it is important to be aware
of such differences, inferences from mouse models of dis-
ease remain relevant and have, to date, signiﬁcantly
advanced our understanding of FPR biology and neutrophil
function in both the physiological and pathophysiological
states.
FPR1 in Health and Disease
Mitochondrial Formylated Peptides
With regard to neutrophil FPR1 function, the principal
proinﬂammatory effects are mediated through bacterial and
mitochondrial formylated peptides. Given the increasing
interest in the role of FPR1 in sterile inﬂammation, we focus
on the synthesis, release, and function of the latter in greater
detail. It has been proposed that mitochondria arose over 2
billion years ago after the inclusion of a-proteobacteria
within the ancient precursors of eukaryotic cells. Much of
the initial genetic material contained within these bacteria
has either been lost or transferred to the nuclear genome,
which now encodes the vast majority of the approximately
1500 mitochondrial proteins.71 What has been left, however,
is approximately 16 Kb of CpG-rich, unmethylated mito-
chondrial DNA (mtDNA), which encodes for 13 mito-
chondrial peptides that make up the key components of the
respiratory chain within the inner mitochondrial membrane.
In addition, mtDNA also contains coding information of 22
tRNAs and two mitochondrial ribosome (mitoribosome)-
coding RNAs, vital for the processes of translation and
peptide synthesis.72
Distinct from eukaryotic cytoplasmic ribosomes, pro-
karyotic and mitochondrial protein synthesis require an N-
terminal fMet residue to initiate translation. Mitoribosomes
are located in the mitochondrial matrix, with approximately
100 per organelle, and contain 39S and 28S ribosomal1177
Dorward et alsubunits.72 Unlike cytoplasmic mRNA, mitochondrial
mRNA has no upstream leader sequence to coordinate
mitoribosome binding but instead starts at the 50 end, with the
N-terminal fMet binding to the mRNA start codon. N-ter-
minal fMet binding to the small (28S) ribosome is facilitated
by mitochondrial translational initiation factor 2 in a GTP-
dependent process. Importantly, it is only N-terminal fMet
and not Met-tRNA that is recognized by mitochondrial
translational initiation factor 2 as the initiator tRNA, hence
the crucial and irreplaceable nature of fMet in mitochondrial
peptide synthesis.73
Although extracellular mitochondrial formylated pep-
tides are recognized as potent damage-associated molecular
patterns, within mitochondria they are naturally subjected to
post-translational modiﬁcation. Some peptides, however,
undergo removal of the formyl group which principally
occurs through the action of peptide deformylase, a zinc-
and iron-binding metalloproteinase that hydrolytically
cleaves the N-terminal formyl moiety.74 Inhibition of pep-
tide deformylase causes a global reduction in the accumu-
lation of mtDNA-encoded proteins, with impaired
subsequent assembly of components of the respiratory chain
and therefore mitochondrial energy production.75 Despite
these observations, the exact role and contribution of pep-
tide deformylase and the balance between mature formylated
and deformylated peptides within the mitochondria remain
poorly understood. Importantly, it appears that peptide defor-
mylase is not capable of deformylating all mitochondria-
synthesized peptides.76 Indeed, deformylation does not
completely remove the presence of formylated peptides within
eukaryotic cells, as both formylated and deformylated versions
of the same peptides coexist.75 It is also interesting to note that
extracellular deformylase enzymes within rat intestinal mucosa
that sequentially cleave bacterial formylated peptides to reduce
the abundance of proinﬂammatory mediators have been
described.77
At present, there is no direct evidence of active release of
mitochondrial formylated peptides from cells; rather, it is
considered a passive process after necrotic cell death. This
method of release is obviously distinct from bacteria, which
can actively secrete formylated peptides into the extracellular
milieu.78 Given the description of autophagy-mediated high-
mobility group box protein 1 (HMGB1), IL-1b, mtDNA, and
ATP release, it is not inconceivable that formylated peptides
are also actively released by similar mechanisms.79
FPR1 in Sterile Inﬂammation
The importance of mitochondrial formylated peptides in
inﬂuencing neutrophil function was originally described by
Carp,7 who demonstrated their ability in vitro, distinct from
nonformylated mitochondrial proteins, to induce neutrophil
chemotaxis through binding to FPR1. This ﬁnding was
substantiated by the subsequent demonstration of their
ability to induce neutrophil-like promyelocytic HL-60 cell
intracellular calcium ﬂux and superoxide anion production1178through binding to both FPR1 and FPR2/ALX.38 Further
appreciation of their in vivo signiﬁcance as important
damage-associated molecular patterns came with the
description of elevated mtDNA levels, as a general marker
of liberated mitochondrial products, in the circulation of
patients with aseptic, trauma-induced systemic inﬂamma-
tory response syndrome.30 Alongside this observation,
Zhang et al30 demonstrated the FPR1-dependent peritoneal
neutrophil recruitment after i.p. injection of isolated
mitochondrial damage-associated molecular patterns.
Furthermore, they were able to induce alveolar neutrophil
accumulation and pulmonary extravascular leak after i.v.
administration of mitochondrial damage-associated molec-
ular patterns in rats. Together with further in vitro demon-
stration of mitochondrial damage-associated molecular
patternseinduced FPR1-dependent chemotaxis, intracel-
lular calcium ﬂux, and degranulation, they provided the ﬁrst
robust evidence of the in vivo importance of mitochondrial
formylated peptideemediated neutrophil activation and
migration in driving local and distant inﬂammation.30,80,81
These ﬁndings have subsequently been supported by the
discovery that, in a mouse model of paracetamol-induced
liver injury in which increased levels of circulating
mtDNA were detected, dual blockade of FPR1 and chemokine
(C-X-C motif) receptor 2 attenuated both local hepatotoxicity
and distant neutrophil migration into the lung.82
Alongside these important observations, the role of
mitochondrial formylated peptides was further emphasized
in eloquent work using a mouse model of focal heate
induced sterile liver injury and studied with spinning-disk
intravital microscopy.83 After hepatic necrosis, intravas-
cular gradients of chemokines such as macrophage inhib-
itory protein 2, interacting with chemokine (C-X-C motif)
receptor 2, were shown to guide neutrophils crawling along
the vascular endothelium to regions of sterile inﬂamma-
tion. Having arrived within the vascular system, neutro-
phils then sensed formylated peptides, exiting the capillary
bed and moving through the tissue toward the area of ne-
crosis in an FPR1-dependent manner. This observation was
conﬁrmed by the nondirectional migration of FPR1/
neutrophils within the tissue and their failure to enter the
necrotic zone, distinct from wild-type neutrophils, which
rapidly accumulated within the necrotic area generated by
the thermal injury.83 Importantly, this appears not to be an
organ-speciﬁc phenomenon, as the same hierarchy of
chemotactic signals was observed within areas of sterile
skin inﬂammation even though the route of neutrophil
migration was predominantly interstitial rather than
intravascular.84
Understanding of the neutrophil response to infection
explains the potentially signiﬁcant role of mitochondrial
formylated peptides in the inﬂammatory process. As neu-
trophils are essential for bacterial clearance, they need to
rapidly migrate through tissues and localize invading
pathogens by responding to bacteria-derived chemo-
attractants, including formylated peptides, and not beajp.amjpathol.org - The American Journal of Pathology
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surrounding inﬂammatory milieu.85 The dominant role of
bacterial formylated peptides, in the presence of other
competing mediators, in driving neutrophil chemotaxis
has been recently described.47 Interstitial neutrophil
migration is mediated by PI3K and p38 MAPK signaling
pathways, with the latter the more dominant process. In an
environment of multiple signaling mediators, neutrophil
PI3K is inactivated by phosphatase and tensin homologue,
allowing p38 and phospholipase A2 to drive neutrophil
migration toward bacterial products.47 In Pten/ mice, this
effect is lost and neutrophils fail to prioritize and become
distracted by other chemokines, leading to impaired neutrophil
migration with a subsequent reduction in bacterial clearance
in vivo.47 As mitochondrial formylated peptides appear to exert
a similarly dominant hierarchical effect on neutrophil migration
and function, their putative importance in the pathogenesis of
sterile inﬂammation and tissue injury is clear.86
FPR1 and Infection
The classic description of the role of FPR1 is in the migration
of neutrophils into sites of infection for the subsequent
containment and killing of the microorganism. Although this
role had been suggested from in vitro observations,83 it was
the generation of the Fpr1/ mouse that allowed for the
demonstration of this role in vivo.87 Replacement of a 150-bp
sequence with a neomycin-resistance cassette of the Fpr1
gene, within the part encoding for the ﬁrst extracellular loop to
the fourth transmembrane domain, allowed for the complete
absence of Fpr1 expression at both the protein and mRNA
levels. The neutrophils were shown to be completely unre-
sponsive to formylated peptides with regard to intracellular
calcium ﬂux as well as chemotaxis both in vitro and in vivo.87
Injection of i.v. L. monocytogenes resulted in increased bac-
terial load in both the liver and spleen of Fpr1/ mice relative
to wild-type mice, attributable to reductions in neutrophil
migration and diminished ROS production.46,87 Furthermore,
Streptococcus pneumoniae meningeal infection is associated
with poorer outcome in Fpr1/ animals but, interestingly, a
paradoxical increase in neutrophil number within the brain.88
Consistent with FPR1 having a central role in pathogen
containment, S. aureus secretes an FPR1 inhibitory protein as
a potential immune-evasion strategy.89
In contrast, within the lung, susceptibility to pulmonary S.
pneumoniae infection is not increased in Fpr1/ mice or in
wild-type animals treated with pharmacological inhibitors of
FPR1, such as cyclosporin H.90,91 Indeed, a reduction in
neutrophil number after pharmacological FPR1 inhibition
has instead been demonstrated to have no effect on bacterial
burden.91 In a model of bacterial endotoxin-mediated lung
injury, Fpr1/ mice had a reduction in alveolar, interstitial,
and circulating neutrophil numbers, as well as extravascular
leak, 4 hours after injury with nebulized LPS.92 Whether
these seemingly paradoxical observations are due to organ,
pathogen, or model-speciﬁc differences remains to be seen.The American Journal of Pathology - ajp.amjpathol.orgCigarette smoke contains a wide variety of bacterial prod-
ucts, including LPS and formylated peptides.93 Demonstrating
the importance of FPR1 in both the initiation and propagation of
pulmonary inﬂammation, Cardini et al94 found that wild-type
mice chronically exposed to cigarette smoke over a 7-month
period developed characteristic emphysematous changes. In
contrast, Fpr1/ animals were protected from emphysema,
suggesting that the formylated peptides within cigarette smoke
are central to disease pathogenesis. A similarly beneﬁcial
reduction in inﬂammatory response, with fewer migrating
neutrophils and macrophages and lower proinﬂammatory
cytokine levels, was observed after acute or subacute exposure
(1 to 3 days) to cigarette smoke.94Whether the chronic changes
observed are attributable to an alteration in initial inﬂammatory
cell phenotype or are a result of a modulation of the chronic
inﬂammatory response through both innate and adaptive
immune response remains to be elucidated.
Further novel perspectives on the role of FPR1 in infec-
tion have come through the description of the essential role
of neutrophil-derived IL-1b in abscess formation and bac-
terial clearance after cutaneous S. aureus infection.95
Alongside animals deﬁcient in Toll-like receptor (Tlr) 2
and nucleotide-binding oligomerization domain (Nod) 2,
Fpr1/ mice were noted to have a reduced neutrophil
number at the site of infection, with an associated reduction
in IL-1b release after direct bacterial infection in vitro,
suggesting another mechanism through which this GPCR
exerts its antibacterial functions.95
FPR1 in Other Cell Types
Themost frequently described roles for FPR1 are with regard to
neutrophil chemotaxis, degranulation, and ROS production, but
FPR1 activation also exerts effects in other cell types. In iso-
lated humanmonocytes, FPR1 activation augments IL-8 release
in a manner cooperative with other mitochondrial damage-
associated molecular patterns31 while also inﬂuencing dendritic
cell maturation, migration, and phenotype.33,96 Importantly, the
number of FPR1 receptors on the macrophage surface appears
linked to their phenotype, at least in vitro, as treatment with
cytokines associated with inducing an alternatively activated
phenotype (IL-4 and IL-13) reduced FPR1 through Stat6-
dependent mechanisms, whereas interferon g (associated with
a classically activated phenotype) increased receptor expres-
sion.97,98 Importantly, in the former group, fMLF-induced
migration was completely abrogated, suggesting regulation of
cell migration into the inﬂammatory environment by autocrine
and paracrine manipulation of GPCR expression.
In addition to the direct regulation of immune cells, the
role of bacteria-derived formylated peptides in mediating
nociceptive responses to infection has recently been delin-
eated. S. aureus skin infection causes hyperalgesic re-
sponses that were found to be independent of inﬁltrating
immune cells but instead dependent on formylated peptides
and the bacterial pore-forming toxin a-hemolysin, with
protection in Fpr1/ mice noted.99 Interestingly, inhibition1179
Dorward et alof nociceptor responses led to enhanced local inﬂammation,
demonstrating that formylated peptides can have indirect
immune-modulatory properties acting via neuronal cell
types.99
Recent evidence has also emerged of a protective role for
FPR1 in the maintenance of epithelial integrity and mucosal
repair after colonic injury in vivo. Indeed, formylated peptides
released by commensal bacteria within the colon promote
enterocyte migration and proliferation through FPR1 and
NADPH oxidase 1.100 Furthermore, binding of AnnA1 and
Ac2-26, its N-terminal derivative, to epithelial FPR1 results in
Src kinase andNADPHoxidase 1 activation and increasedROS
production. Subsequent oxidative inactivation of regulatory
phosphatases, phosphatase and tensin homologue, and protein
tyrosine phosphatase containing proline, glutamic acid, serine,
and threonine residues (PTP-PEST) leads to paxillin and focal
adhesion kinaseemediated epithelial migration and wound
closure.35 In vivo, delivery of exogenous AnnA1 resulted in
accelerated recovery after chemical-induced colitis.35
Despite this latter observation, a similarly important role
for FPR1 has been seen in vitro in human bronchial
epithelial cell migration, with an FPR1-dependent response
to mitochondrial formylated peptides observed after linear
scratch injury to cells in culture.101 The in vivo corollary and
functional relevance of FPR1-mediated pulmonary epithe-
lial homeostasis is, however, yet to be established.101
Additional evidence for the importance of Fpr1 in epithe-
lial homeostasis lies in the observation that Fpr1/ mice
develop spontaneous lens degeneration in the absence of
any preceding inﬂammatory events,102 whereas the presence
of formylated peptides accelerates human retinal pigment
epithelial cell migration after injury.103 Conversely, up-
regulation of expression in malignant cells may confer a
more aggressive and invasive phenotype due to an increased
propensity of cells to migrate.104
In keratinocytes, FPR1 has been shown, within speciﬁc
clinical contexts, to play an important role in the control of
necroptosis (caspase-independent programed cell death). In
patientswith severe blistering skin conditions, such as Stevens-
Johnson syndrome, keratinocytes, when cultured in vitro,were
sensitive to the FPR1 agonists fMLF and AnnA1, resulting in
necroptosis through ROS production and receptor-interacting
protein.36 The limited nature of this observation is attributed
to differences in inducible expression of FPR1, which is
greater in Stevens-Johnson syndrome than in other similar
dermatological conditions despite no differences in promoter
sequence.36 This role in keratinocyte death is in contrast to the
proposed beneﬁcial effects of FPR1,35 in particular on binding
AnnA1, in the maintenance of gastrointestinal epithelial
integrity and warrants further investigation.Inhibition of FPR1
Accompanying the increased understanding of the patho-
physiological role of FPR1 is the appreciation of its1180potential as a therapeutic target in chronic inﬂammatory
disorders or acute sterile inﬂammation either through the
use of agonists or antagonists, depending on the context.
With regard to pharmacological antagonists, there are, at
present, limited FPR1-speciﬁc compounds available.
Initially, Boc-Met-Leu-Phe-OH (Boc-MLF; alias Boc-1)
and subsequent Boc-Phe-Leu-Phe-Leu-Phe-OH (Boc-
FLFLF; alias Boc-2) were described,105 but their relative
low potency and lack of speciﬁcity given associated FPR2
inhibition have led to cyclosporin H, an inverse agonist to
FPR1, being the more readily used agent in preclinical
studies.80,83,91,94 Its speciﬁcity is limited by the off-target
effects on calcium/calmodulinedependent phosphoryla-
tion of elongation factor 2.106 Studies that are based on
observations made entirely using these compounds should
therefore be interpreted with caution and need to be
accompanied by adjunctive demonstrations of FPR1 inhi-
bition with monoclonal antibodies or, in the murine context,
the use of Fpr1 knockout animals.
Emphasis has therefore shifted to the development of
alternative synthetic peptide ligands and small molecules,
agonists and antagonists that were recently reviewed else-
where.106 Several synthetic ligands inhibiting fMLF-
induced neutrophil chemotaxis have been described107,108;
however, their inhibitory effects may be through the inhi-
bition of downstream signaling pathways rather than direct
FPR1 antagonism. Given difﬁculties in the synthesis and
delivery of peptides, a complementary focus has been on the
development of small-molecule antagonists and the use of
high-throughput screening and structureeactivity relation-
shipedirected design and synthesis.109,110 Notably, this
approach has recently identiﬁed particular chromones and
isoﬂavones that are selective for FPR1 and do not alter
FPR2-mediated ERK phosphorylation and intracellular
calcium ﬂux.111Conclusion
FPR1, as a stereotypical GPCR, has facilitated signiﬁcant
advances in our understanding of receptor signaling and
control of multiple cell functions at a single-cell level. It has,
however, been the identiﬁcation of surrogate biomarkers of
the release of mitochondrial products (elevated plasma
mtDNA in trauma, sepsis, and systemic inﬂammatory
response syndrome), the development and application of
transgenic mouse models into a variety of disease models,
and the awareness of FPR1 functions in nonmyeloid cells
that has now ﬁrmly established the functional importance of
FPR1 in the pathophysiology of a plethora of inﬂammatory
diseases. Whether FPR1 antagonism, which interferes with
the bactericidal capacity of neutrophils, risks precipitating or
exacerbating intercurrent infection remains to be shown in
appropriate animal models. However, in the context of the
many neutrophil-dominant sterile inﬂammatory disease
processes that affect humans, FPR1 antagonism may proveajp.amjpathol.org - The American Journal of Pathology
FPR1 in Acute Neutrophilic Inﬂammationbeneﬁcial. Therefore, the development of small-molecule
antagonists and the appreciation of its ligand-dependent and
potential proresolution effects have placed FPR1 in the
arena of attractive novel therapeutic targets.
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